Journal of the American Academy of Dermatology
Volume 60, Issue 2 , Pages 218-224 , February 2009

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004

  • Shanu Kohli Kurd, MHS

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Joel M. Gelfand, MD, MSCE

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Corresponding Author InformationCorrespondence to: Joel M. Gelfand, MD, MSCE, University of Pennsylvania, Department of Dermatology, 3600 Spruce St, 2 Maloney Building Suite 2M47, Philadelphia, PA 19104.

,Accepted 17 September 2008.

References 

  1. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416–422
  2. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493–1499
  3. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741
  4. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835
  5. Kurd S, Richardson S, Gelfand J. An update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol. 2007;3:171–185
  6. Gelfand JM, Azfar RS, Shin DB, Kurd SK, Wang X, Troxel AB. Incidence of stroke in patients with psoriasis: a population–based study. J Invest Dermatol. 2008;128:S81
  7. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007;143:239–242
  8. Gelfand JM. Long-term treatment for severe psoriasis: we're halfway there, with a long way to go. Arch Dermatol. 2007;143:1191–1193
  9. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–496
  10. Johnson M, Roberts J. Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974. Vital Health Stat. 1978;11:72
  11. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996;135:533–537
  12. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol. 1984;10:965–968
  13. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–1541
  14. Psoriasis Hellgren L. A statistical, clinical and laboratory investigation of 255 psoriatics and matched healthy controls. Acta Derm Venereol. 1964;44:191–207
  15. Kavli G, Stenvold SE, Vandbakk O. Low prevalence of psoriasis in Norwegian lapps. Acta Derm Venereol. 1985;65:262–263
  16. Ferrandiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol. 2001;15:20–23
  17. Lomholt G. Psoriasis on the Faroe Islands; a preliminary report. Acta Derm Venereol. 1954;34:92
  18. Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S. Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl (Stockh). 1989;146:178–179
  19. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol. 1981;61:344–346
  20. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121–128
  21. Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl (Stockh). 1993;182:6–9
  22. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med. 1976;30:107–114
  23. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23–26
  24. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139
  25. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev Dermatol. 2006;1:63–75
  26. Kavli G, Forde OH, Arnesen E, Stenvold SE. Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed). 1985;291:999–1000
  27. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–708
  28. National Psoriasis Foundation. About psoriasis: statistics. Available at: http://www.psoriasis.org/about/stats/. Accessed November 6, 2008.
  29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  30. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573
  31. Feldman SR, Fleischer AB, Reboussin DM, Rapp SR, Exum ML, Clark AR, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. 1996;106:183–186
  32. Martin LM, Leff M, Calonge N, Garrett C, Nelson DE. Validation of self-reported chronic conditions and health services in a managed care population. Am J Prev Med. 2000;18:215–218

 Supported in part by a National Research Service Award from the National Institute of Health (to S.K.K.) and a grant K23AR051125 from the National Institutes of Health/National Institute of Arthritis, Musculoskeletal, and Skin Diseases (to J.M.G.).

 Conflicts of interest: None declared.

 Reprints not available from the authors.

PII: S0190-9622(08)01201-2

doi: 10.1016/j.jaad.2008.09.022

Journal of the American Academy of Dermatology
Volume 60, Issue 2 , Pages 218-224 , February 2009

Article Tools